Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer ... - Marketscreener.com
NVIVDelisted Stock | USD 1.38 0.07 5.34% |
Slightly above 55% of InVivo Therapeutics' sophisticated investors are presently thinking to get in. The analysis of current outlook of investing in InVivo Therapeutics Holdings suggests that some traders are interested regarding InVivo Therapeutics' prospects. InVivo Therapeutics' investing sentiment can be driven by a variety of factors including economic data, InVivo Therapeutics' earnings reports, geopolitical events, and overall market trends.
InVivo |
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer ... Marketscreener.com
Read at news.google.com
InVivo Therapeutics Fundamental Analysis
We analyze InVivo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InVivo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InVivo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
InVivo Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
InVivo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InVivo Therapeutics stock to make a market-neutral strategy. Peer analysis of InVivo Therapeutics could also be used in its relative valuation, which is a method of valuing InVivo Therapeutics by comparing valuation metrics with similar companies.
Peers
InVivo Therapeutics Related Equities
NXTC | NextCure | 2.75 | ||||
SABS | SAB Biotherapeutics | 2.60 | ||||
ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
NTRB | Nutriband | 0.00 | ||||
SNTI | Senti Biosciences | 0.18 | ||||
RNXT | RenovoRx | 0.76 | ||||
ASMB | Assembly Biosciences | 1.43 | ||||
MOLN | Molecular Partners | 2.16 | ||||
SPRO | Spero Therapeutics | 2.73 | ||||
RZLT | Rezolute | 3.23 | ||||
KPRX | Kiora Pharmaceuticals | 3.57 | ||||
CTMX | CytomX Therapeutics | 3.57 | ||||
HCWB | HCW Biologics | 4.87 | ||||
LGVN | Longeveron LLC | 5.10 | ||||
VRAX | Virax Biolabs | 8.82 | ||||
QNRX | Quoin Pharmaceuticals | 10.40 | ||||
REVB | Revelation Biosciences | 11.95 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world |